This chapter examines regulation, a very specific dimension of commercial biotech development, and the ways in which the state in Korea, Taiwan, and Singapore has both contributed to and attempted to manage regulatory uncertainty. It shows that the state in Korea, Taiwan, and Singapore has experienced both interest alignment and unalignment in the regulation of the biotechnology sector. In some areas of the regulatory process, decision makers in all three countries have been able to align various interests relatively easily, providing a fair degree of regulatory clarity and certainty. This is best exemplified in the early regulation of clinical R and D. States have also established a relatively coherent stance in bioethics regulation, but have largely failed to resolve intrastate conflicts about the regulation of health technology markets.
Cornell Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.